BRPI1010874A8 - composição para o tratamento de câncer de próstata - Google Patents

composição para o tratamento de câncer de próstata

Info

Publication number: BRPI1010874A8
Authority: BR; Brazil
Prior art keywords: composition; prostate cancer; cancer treatment; treatment; prostate
Prior art date: 2009-05-01

Application number

BRPI1010874A

Other languages

English (en)

Inventor

Erichsen Lars

Cantor Per

Kold Olesen Tine

Original Assignee

Ferring Bv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-05-01

Filing date

2010-04-30

Publication date

2018-01-02

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41066059&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI1010874(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-04-30 Application filed by Ferring Bv filed Critical Ferring Bv

2017-05-30 Publication of BRPI1010874A2 publication Critical patent/BRPI1010874A2/pt

2018-01-02 Publication of BRPI1010874A8 publication Critical patent/BRPI1010874A8/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Dermatology (AREA)
Chemical Kinetics & Catalysis (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Reproductive Health (AREA)
Endocrinology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Tropical Medicine & Parasitology (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Plant Substances (AREA)

BRPI1010874A 2009-05-01 2010-04-30 composição para o tratamento de câncer de próstata BRPI1010874A8 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP09251242		2009-05-01
US18781909P	2009-06-17	2009-06-17
PCT/IB2010/001063 WO2010125468A1 (en)	2009-05-01	2010-04-30	Composition for the treatment of prostate cancer

Publications (2)

Publication Number	Publication Date
BRPI1010874A2 BRPI1010874A2 (pt)	2017-05-30
BRPI1010874A8 true BRPI1010874A8 (pt)	2018-01-02

Family

ID=41066059

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI1010874A BRPI1010874A8 (pt)	2009-05-01	2010-04-30	composição para o tratamento de câncer de próstata

Country Status (18)

Country	Link
US (1)	US8722088B2 (pt)
EP (1)	EP2424503B1 (pt)
JP (5)	JP5973909B2 (pt)
KR (1)	KR101795643B1 (pt)
CN (2)	CN105663059A (pt)
AR (1)	AR078224A1 (pt)
AU (1)	AU2010243273B2 (pt)
BR (1)	BRPI1010874A8 (pt)
CA (1)	CA2759888A1 (pt)
ES (1)	ES2641767T3 (pt)
IL (1)	IL215772A (pt)
MX (1)	MX2011011431A (pt)
NZ (1)	NZ595767A (pt)
RU (1)	RU2536245C2 (pt)
SA (1)	SA110310340B1 (pt)
TW (2)	TWI508734B (pt)
WO (1)	WO2010125468A1 (pt)
ZA (1)	ZA201107879B (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0117057D0 (en) *	2001-07-12	2001-09-05	Ferring Bv	Pharmaceutical composition
TWI539959B (zh)	2008-02-11	2016-07-01	菲瑞茵國際中心股份有限公司	治療轉移階段攝護腺癌的方法
ES2641767T3 (es)	2009-05-01	2017-11-13	Ferring Bv	Composición para el tratamiento del cáncer de próstata
US20110039787A1 (en) *	2009-07-06	2011-02-17	Ferring International Center S.A.	Compositions, kits and methods for treating benign prostate hyperplasia
SI3564357T1 (sl)	2010-02-01	2022-09-30	Rebiotix, Inc.	Bakterioterapija Clostridium Difficile colitisa
ES2617336T3 (es)	2010-10-27	2017-06-16	Ferring B.V.	Procedimiento para la fabricación de degarelix y sus productos intermedios
EP2447276A1 (en)	2010-10-27	2012-05-02	Ferring B.V.	Process for the manufacture of Degarelix and its intermediates
JO3755B1 (ar)	2011-01-26	2021-01-31	Ferring Bv	تركيبات تستوستيرون
CN102204889B (zh) *	2011-05-23	2013-09-18	蚌埠丰原涂山制药有限公司	一种醋酸地加瑞克冻干粉针剂及其制备方法
EP4512389A3 (en)	2012-06-01	2025-06-18	Ferring B.V.	Degarelix drug product
CN105473152A (zh)	2013-06-05	2016-04-06	雷柏奥提斯有限公司	菌群恢复疗法（mrt）、组合物和制造方法
US10828340B2 (en)	2015-06-09	2020-11-10	Rebiotix, Inc.	Microbiota restoration therapy (MRT) compositions and methods of manufacture
TWI571254B (zh) *	2016-01-08	2017-02-21	誠熱實業股份有限公司	放射治療用之醫療輔助裝置
CN105769774A (zh) *	2016-03-02	2016-07-20	张光泉	一种注射用醋酸地加瑞克冻干组合物及其制备方法
US10933134B2 (en) *	2017-03-16	2021-03-02	Memorial Sloan Kettering Cancer Center	Combination therapies for treatment of cancer
RU2731002C1 (ru) *	2019-10-22	2020-08-26	Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского)	Способ лечения рака предстательной железы

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3773919A (en)	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
EP0002749B2 (en)	1977-12-26	1987-08-12	IHARA CHEMICAL INDUSTRY Co., Ltd.	Process for producing aromatic monocarboxylic acid
WO1992019651A1 (en)	1991-04-25	1992-11-12	Romano Deghenghi	Luteinizing hormone releasing hormone antagonist peptides
DE69330107T3 (de)	1992-02-12	2004-12-30	Daikyo Gomu Seiko, Ltd.	Medizinisches Gerät
SI9300468A (en)	1992-10-14	1994-06-30	Hoffmann La Roche	Injectable composition for the sustained release of biologically active compounds
US5506207A (en)	1994-03-18	1996-04-09	The Salk Institute For Biological Studies	GNRH antagonists XIII
US5595760A (en)	1994-09-02	1997-01-21	Delab	Sustained release of peptides from pharmaceutical compositions
US5860957A (en)	1997-02-07	1999-01-19	Sarcos, Inc.	Multipathway electronically-controlled drug delivery system
US5925730A (en)	1997-04-11	1999-07-20	Ferring Bv	GnRH antagonists
US5821230A (en)	1997-04-11	1998-10-13	Ferring Bv	GnRH antagonist decapeptides
FR2776520B1 (fr)	1998-03-25	2000-05-05	Sod Conseils Rech Applic	Nouvelles compositions pharmaceutiques destinees a la liberation prolongee de peptides et leur procede de preparation
US20040198706A1 (en)	2003-03-11	2004-10-07	Carrara Dario Norberto R.	Methods and formulations for transdermal or transmucosal application of active agents
WO2003006079A1 (en) *	2001-07-11	2003-01-23	Sca Hygiene Products Ab	Coupling of modified cyclodextrins to fibers
GB0117057D0 (en)	2001-07-12	2001-09-05	Ferring Bv	Pharmaceutical composition
US7098305B2 (en) *	2001-09-06	2006-08-29	Ardana Bioscience Limited	Sustained release of microcrystalline peptide suspensions
CN1411803A (zh)	2002-08-29	2003-04-23	四川大学	制备前体脂质体的方法及其装置
CA2507524C (en) *	2002-09-27	2012-12-11	Zentaris Gmbh	Administration form for pharmaceutically active peptides with sustained release and method for the production thereof
AR042815A1 (es)	2002-12-26	2005-07-06	Alza Corp	Dispositivo de suministro de agente activo que tiene miembros compuestos
EP1674082A1 (de)	2004-12-22	2006-06-28	Zentaris GmbH	Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel
WO2007130809A2 (en)	2006-05-06	2007-11-15	Volodymyr Brodskyy	An automatic injectable drug mixing device
EP1891964A1 (en)	2006-08-08	2008-02-27	AEterna Zentaris GmbH	Application of initial doses of LHRH analogues and maintenance doses of LHRH antagonists for the treatment of hormone-dependent cancers and corresponding pharmaceutical kits
EP1967202A1 (en)	2007-03-05	2008-09-10	AEterna Zentaris GmbH	Use of LHRH Antagonists for the Treatment of Lower Urinary Tract Symptoms, in particular Overactive Bladder and/or Detrusor Overactivity
IL182922A0 (en)	2007-05-02	2007-09-20	Medimop Medical Projects Ltd	Automatic liquid drug reconstitution apparatus
ES2589322T3 (es)	2008-02-11	2016-11-11	Safety Syringes, Inc.	Jeringa con protector de seguridad de aguja y clip para evitar la liberación del protector durante un proceso de reconstitución
TWI539959B (zh)	2008-02-11	2016-07-01	菲瑞茵國際中心股份有限公司	治療轉移階段攝護腺癌的方法
ES2641767T3 (es)	2009-05-01	2017-11-13	Ferring Bv	Composición para el tratamiento del cáncer de próstata
TW201043221A (en)	2009-05-06	2010-12-16	Ferring Int Ct Sa	Kit and method for preparation of a Degarelix solution
US20110039787A1 (en)	2009-07-06	2011-02-17	Ferring International Center S.A.	Compositions, kits and methods for treating benign prostate hyperplasia
EP2447276A1 (en)	2010-10-27	2012-05-02	Ferring B.V.	Process for the manufacture of Degarelix and its intermediates
ES2617336T3 (es)	2010-10-27	2017-06-16	Ferring B.V.	Procedimiento para la fabricación de degarelix y sus productos intermedios
JO3755B1 (ar)	2011-01-26	2021-01-31	Ferring Bv	تركيبات تستوستيرون
PL2731607T3 (pl)	2011-07-15	2018-03-30	Ferring B.V.	Sposób koordynacji czasu kolonoskopii, w którym podaje się kompozycję pikosiarczanową

2010
- 2010-04-30 ES ES10726197.6T patent/ES2641767T3/es active Active
- 2010-04-30 AR ARP100101489A patent/AR078224A1/es not_active Application Discontinuation
- 2010-04-30 CA CA2759888A patent/CA2759888A1/en not_active Abandoned
- 2010-04-30 JP JP2012507846A patent/JP5973909B2/ja active Active
- 2010-04-30 AU AU2010243273A patent/AU2010243273B2/en active Active
- 2010-04-30 CN CN201610082160.4A patent/CN105663059A/zh active Pending
- 2010-04-30 MX MX2011011431A patent/MX2011011431A/es active IP Right Grant
- 2010-04-30 WO PCT/IB2010/001063 patent/WO2010125468A1/en active Application Filing
- 2010-04-30 RU RU2011142843/15A patent/RU2536245C2/ru active
- 2010-04-30 NZ NZ595767A patent/NZ595767A/xx unknown
- 2010-04-30 TW TW099113849A patent/TWI508734B/zh active
- 2010-04-30 KR KR1020117025625A patent/KR101795643B1/ko active Active
- 2010-04-30 US US12/771,199 patent/US8722088B2/en active Active
- 2010-04-30 TW TW104130953A patent/TWI583391B/zh active
- 2010-04-30 CN CN2010800191738A patent/CN102421414A/zh active Pending
- 2010-04-30 EP EP10726197.6A patent/EP2424503B1/en active Active
- 2010-04-30 BR BRPI1010874A patent/BRPI1010874A8/pt not_active Application Discontinuation
- 2010-05-01 SA SA110310340A patent/SA110310340B1/ar unknown
2011
- 2011-10-23 IL IL215772A patent/IL215772A/en active IP Right Grant
- 2011-10-27 ZA ZA2011/07879A patent/ZA201107879B/en unknown
2015
- 2015-03-24 JP JP2015060929A patent/JP6462447B2/ja active Active
2020
- 2020-07-30 JP JP2020129078A patent/JP7296922B2/ja active Active
2022
- 2022-03-29 JP JP2022052785A patent/JP7297116B2/ja active Active
2023
- 2023-04-21 JP JP2023069860A patent/JP7665674B2/ja active Active

Also Published As

Publication number	Publication date
US8722088B2 (en)	2014-05-13
SA110310340B1 (ar)	2015-02-04
CN105663059A (zh)	2016-06-15
AU2010243273B2 (en)	2016-06-16
ES2641767T3 (es)	2017-11-13
TW201600106A (zh)	2016-01-01
JP7296922B2 (ja)	2023-06-23
KR20120015310A (ko)	2012-02-21
JP2020183444A (ja)	2020-11-12
JP7297116B2 (ja)	2023-06-23
JP2012525373A (ja)	2012-10-22
JP2015157818A (ja)	2015-09-03
NZ595767A (en)	2012-12-21
CN102421414A (zh)	2012-04-18
AU2010243273A1 (en)	2011-11-10
EP2424503A1 (en)	2012-03-07
JP2023093643A (ja)	2023-07-04
EP2424503B1 (en)	2017-07-05
KR101795643B1 (ko)	2017-11-09
TWI583391B (zh)	2017-05-21
ZA201107879B (en)	2012-07-25
TW201039840A (en)	2010-11-16
RU2536245C2 (ru)	2014-12-20
TWI508734B (zh)	2015-11-21
JP6462447B2 (ja)	2019-01-30
IL215772A0 (en)	2012-01-31
CA2759888A1 (en)	2010-11-04
BRPI1010874A2 (pt)	2017-05-30
AR078224A1 (es)	2011-10-26
JP7665674B2 (ja)	2025-04-21
US20100305042A1 (en)	2010-12-02
WO2010125468A1 (en)	2010-11-04
IL215772A (en)	2016-10-31
MX2011011431A (es)	2012-02-23
JP5973909B2 (ja)	2016-08-23
RU2011142843A (ru)	2013-06-10
JP2022088517A (ja)	2022-06-14

Publication	Publication Date	Title
BRPI1010874A8 (pt)	2018-01-02	composição para o tratamento de câncer de próstata
BR112012005594A2 (pt)	2015-09-08	tratamento de câncer
BRPI1007972A2 (pt)	2016-09-13	composições de combinação e métodos para o tratamento de câncer
BRPI1013618A2 (pt)	2016-04-19	pirimidinas substituídas para o tratamento de câncer
BRPI1015215A2 (pt)	2016-06-28	porções de ligação alvo armadas com amatoxina para o tratamento de câncer
BRPI0919238A2 (pt)	2019-09-24	métodos e composições para o tratamento de câncer
BR112012002797A2 (pt)	2019-09-24	tratamento de câncer de próstata
BRPI1008566A2 (pt)	2017-06-06	métodos e composições para o diagnóstico e tratamento de câncer
PT2434891T (pt)	2020-10-23	Métodos para tratamento de cancro e afeções não neoplásicas
BRPI0818320A2 (pt)	2015-09-08	composição para tratamento de câncer de próstata (pca)
PL2440545T3 (pl)	2019-11-29	Związki użyteczne do leczenia nowotworu
BRPI1008564A2 (pt)	2018-02-27	métodos e composições para o dignóstico e tratamento de câncer
BRPI1006438A2 (pt)	2016-09-27	terapia adjuvante de cancer
EP2627333A4 (en)	2014-03-19	Combination treatment of cancer
BRPI1007995A2 (pt)	2019-09-24	orto-aminoamidas para o tratamento de cãncer.
BRPI0909164A2 (pt)	2016-06-21	método e composições para o tratamento de câncer
BRPI1009919A2 (pt)	2017-03-28	combinações de pentamidina para tratamento de câncer.
BRPI0922884A2 (pt)	2018-11-06	compostos para tratamento de câncer
BRPI0911112A2 (pt)	2015-10-06	composições e métodos para o tratamento do câncer de mama
EP2496244A4 (en)	2013-09-18	PHARMACORESISTANT IMMUNOTHERAPY FOR THE TREATMENT OF CANCER
BRPI0909016A2 (pt)	2015-12-22	anticorpos úteis para o tratamento do câncer
BRPI0922367A2 (pt)	2016-05-24	enzastaurin para o tratamento de câncer
GB0804496D0 (en)	2008-04-16	Treating cancer
HUE038563T2 (hu)	2018-10-29	Rák kezelési eljárás
BRPI0810207A2 (pt)	2014-10-14	Métodos e composições para o tratamento de câncer

Legal Events

Date	Code	Title
2018-01-23	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-04-10	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2021-02-23	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
2021-03-30	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2021-08-10	B09B	Patent application refused [chapter 9.2 patent gazette]
2021-10-19	B12B	Appeal against refusal [chapter 12.2 patent gazette]